🇺🇸 PEGASPARGASE in United States

3,643 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Febrile Neutropenia — 889 reports (24.4%)
  2. Febrile Bone Marrow Aplasia — 530 reports (14.55%)
  3. Pyrexia — 385 reports (10.57%)
  4. Sepsis — 333 reports (9.14%)
  5. Neutropenia — 291 reports (7.99%)
  6. Off Label Use — 260 reports (7.14%)
  7. Hypertriglyceridaemia — 253 reports (6.94%)
  8. Hyperbilirubinaemia — 239 reports (6.56%)
  9. Thrombocytopenia — 238 reports (6.53%)
  10. Mucosal Inflammation — 225 reports (6.18%)

Source database →

PEGASPARGASE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is PEGASPARGASE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for PEGASPARGASE in United States?

Marketing authorisation holder not available in our data.